share_log

Needham Maintains Buy on PhaseBio Pharmaceuticals, Lowers Price Target to $8

Benzinga Real-time News ·  Aug 15, 2022 04:34

Needham analyst Serge Belanger maintains PhaseBio Pharmaceuticals (NASDAQ:PHAS) with a Buy and lowers the price target from $10 to $8.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment